Lupin wins USFDA nod for Bromfenac Ophthalmic Solution

Mumbai: Global pharma major Lupin Limited has announced that the company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.09%.

The product is a generic equivalent of Bromday Ophthalmic Solution, 0.09%, of Bausch & Lomb Inc. Bromfenac Ophthalmic solution, is used for the treatment of swelling or pain of the eyes following cataract surgery.

This product will be manufactured at Lupin’s Pithampur facility in India. Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).

Read also: Lupin bags USFDA nod for Doxycycline Hyclate Delayed Release Tablets

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin gets USFDA approval for generic equivalent of Toprol XL Tablets